BriaCell Therapeutics Corp.
General ticker "BCTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $18.2M (TTM average)
BriaCell Therapeutics Corp. does not follow the US Stock Market performance with the rate: -19.1%.
Estimated limits based on current volatility of 3.3%: low 3.60$, high 3.84$
Factors to consider:
- Total employees count: 22 (+22.2%) as of 2025
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Going concern doubt, Clinical trial failure, Regulatory and compliance, Financing availability, Labor/talent shortage/retention
- Current price 57.4% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-07-31 to 2027-07-31
- 2025-07-31 to 2026-07-31 estimated range: [10.22$, 34.94$]
- 2026-07-31 to 2027-07-31 estimated range: [7.97$, 26.13$]
Financial Metrics affecting the BCTX estimates:
- Negative: with PPE of -0.1 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Negative: negative Industry operating income (median)
- Negative: 0.33 < Interest expense per share per price, % of 0.34
- Negative: Shareholder equity ratio, % of 82.59 > 81.92
- Negative: Investing cash flow per share per price, % of -50.68 <= -40.59
Short-term BCTX quotes
Long-term BCTX plot with estimates
Financial data
| YTD | 2023-07-31 | 2024-07-31 | 2025-07-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $23.27MM | $33.33MM | $27.20MM |
| Operating Income | $-23.27MM | $-33.33MM | $-27.20MM |
| Non-Operating Income | $2.97MM | $28.40MM | $0.65MM |
| Interest Expense | $0.00MM | $0.00MM | $0.05MM |
| R&D Expense | $20.48MM | $27.18MM | $29.50MM |
| Income(Loss) | $-20.30MM | $-4.93MM | $-26.56MM |
| Net Income(Loss)* | $-20.30MM | $-4.79MM | $-26.31MM |
| Stockholders Equity | $-5.04MM | $-3.31MM | $24.58MM |
| Assets | $36.28MM | $8.15MM | $29.77MM |
| Operating Cash Flow | $-23.74MM | $-24.13MM | $-28.17MM |
| Capital expenditure | $0.00MM | $0.62MM | $0.00MM |
| Investing Cash Flow | $0.00MM | $-0.68MM | $-7.65MM |
| Financing Cash Flow | $3.95MM | $4.42MM | $45.45MM |
| Earnings Per Share** | $-19.50 | $-4.37 | $-13.97 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.